ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma

Abstract Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose...

Full description

Saved in:
Bibliographic Details
Main Authors: Marjon A Smit, Gianluca Maddalo, Kylie Greig, Linsey M Raaijmakers, Patricia A Possik, Bas van Breukelen, Salvatore Cappadona, Albert JR Heck, AF Maarten Altelaar, Daniel S Peeper
Format: Article
Language:English
Published: Springer Nature 2014-12-01
Series:Molecular Systems Biology
Subjects:
kinome shRNA genomic screening
PLX4720
proteomics
ROCK1
Online Access:https://doi.org/10.15252/msb.20145450
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/msb.20145450

Similar Items